MUC1 and pulmonary fibrosis: KL-6 has been used and validated as a potential biomarker for diagnosing and indicating the severity and progression of ILD, particularly in idiopathic interstitial pneumonia, including idiopathic pulmonary fibrosis (IPF)23–26.